A jury voted in favor of
Tuesday in a patent dispute case, according to a
The ruling determines in effect that
may not sell Mircera, its rival medicine to Amgen's Aranesp and Epogen anemia drugs, in the U.S.
Amgen shares were rising 87 cents, or 1.6%, to $56.99 in recent trading.